News

InTB Winners Announced!

Inaugural entrants showcase successful new approaches

Thank you to all who submitted entries to the first InnovateTB contest. We are delighted to be able to help promote them as an ongoing effort of the InnovateTB Library.

At the request of our stakeholders, we divided the winners into three categories: Overall Winner, Advocacy Winner (both selected from the popular vote getters by the expert panel), and Fan Favorite (most popular vote getter). We are proud to announce the 2012 InTB Award winners as follows:

Overall Winner

Advocacy Winner

Fan Favorite

ACTION: New technology saves lives

Delft Youth Theatre

The Electronic TB Register

Runner Up

Runner Up

Runner Up

A New Hope for Tuberculosis (MM4TB)

Stop TB’s Challenge Facility for Civil Society

Signature Mapping TBDx

Winners were determined by a combination of popular votes and review by our expert panel members. We would like to thank the panel for their time and guidance:

  • Veronique Dartois — Assistant Professor, Public Health Research Institute, UMDNJ
  • Lucica Ditiu — Executive Secretary, Stop TB Partnership
  • Ken Duncan — Deputy Director, Bill and Melinda Gates Foundation
  • Shobha Shukla — Editor and Director Diabetes Media Initiative, Citizen New Service

Beyond the scope of this contest, InTB aims to catalog and promote groundbreaking work in TB diagnosis, control, and treatment. We invite you to continue to submit innovations to our ongoing library — videos, photos or written accounts for TB innovations you have been involved in.

We look forward to seeing more TB Innovations!

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...